Clinical Trial

Optimizing Clinical Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-edge Repair (M-TEER) for Severe Functional Mitral Regurgitation Towards Improved Guideline-directed Medical Therapy

Study acronym: MOTOR

Terminated

View on ClinicalTrials.gov →

Why the trial stopped

Recruitment too slow

Summary

A multi-centre, prospective, observational pilot registry in patients undergoing mitral valve repair for severe functional mitral regurgitation to report the heart failure drug therapy and dosing before the mitral valve procedure and afterwards to assess whether the recommended maximal dose of medication is administered. This maximal dose, although recommended, might not be tolerated well by patients and can cause side-effects. Researchers will determine whether the mitral valve repair procedure might have a possible effect on increasing the drug therapy towards the recommended optimal doses.

Protocol Amendment History 5 changes

critical Trial status changed: Not Yet Recruiting → Terminated 2026-07-31

critical Trial terminated: Recruitment too slow 2026-07-31

notable Enrollment reduced: 100 -> 9 participants 2026-07-31

notable Primary completion moved earlier: 2026-09-01 -> 2026-03-01 2026-07-31

minor Completion moved earlier: 2026-09-01 -> 2026-03-01 2026-07-31

Trial Details

NCT Number	NCT06702527
Lead Sponsor	Institut für Pharmakologie und Präventive Medizin
Conditions	Mitral Regurgitation Functional, Heart Failure, M-TEER
Enrollment	9 participants
Start Date	2025-04-01
Primary Completion	2026-03-01 (estimated)
Study Completion	2026-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-30